Vanessa Petit

Dr. Vanessa Petit


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
CMCharly Le Maout
Charly Le Maout
LFLucine Fahy
Lucine Fahy
LRLaurent Renou
Laurent Renou
CDCaroline Devanand
Caroline Devanand
CDCharlotte Duwat
Charlotte Duwat
VPVanessa Petit
Vanessa Petit
T-cell acute lymphoblastic leukemia (T-ALL) is a malignant hematological disorder characterized by an increased proliferation of immature T lymphocytes precursors. T-ALL treatment includes chemotherapy with strong side effects, and patients that undergo relapse display poor prognosis. Although cell-intrinsic oncogenic pathways are well-studied, the tumor microenvironment, like inflammatory cellular and molecular components is less explored in T-ALL. We sought to determine the composition of the inflammatory microenvironment induced by T-ALL, and its role in T-ALL progression. We show in two mouse T-ALL cell models that T-ALLs enhance blood neutrophils and resident monocytes, accompanied with a plasmatic acute secretion of inflammatory molecules. Depleting neutrophils using anti-Ly6G treatment or resident monocytes by clodronate liposomes treatment does not modulate plasmatic inflammatory molecule secretion and mice survival. However, inhibiting the secretion of inflammatory molecules by microenvironment with NECA, an agonist of adenosine receptors, diminishes T-ALL progression enhancing mouse survival. We uncovered Hepatocyte Growth Factor (HGF), T-ALL-driven and the most decreased molecule with NECA, as a potential therapeutic target in T-ALL. Altogether, we identified a signature of inflammatory molecules that can potentially be involved in T-ALL evolution and uncovered HGF/cMET pathway as important to target for limiting T-ALL progression.

4 September 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
PRPaul-Henri Romeo
Paul-Henri Romeo
LCLaurine Conquet
Laurine Conquet
SMSébastien Messiaen
Sébastien Messiaen
QPQuentin Pascal
Quentin Pascal
Stéphanie G. MorenoStéphanie G. Moreno
Stéphanie G. Moreno
FFFederica FERRI
Federica FERRI
Few therapeutic options are available to treat COVID-19. The KEAP1/NRF2 pathway, the major redox-responsive pathway, has emerged as a potential therapeutic target for COVID-19 as it regulates redox homeostasis and inflammation that are altered during SARS-CoV-2 infection. Here, we characterized the effects of NRF2-agonist Sulfodyne®, a stabilized natural Sulforaphane, in cellular and animal models of SARS-CoV-2 infection. In pulmonary or colonic epithelial cell lines, Sulfodyne® elicited a more efficient inhibition of SARS-CoV-2 replication than NRF2-agonists DMF and CDDO. This antiviral activity was not dependent on NRF2 but was associated with the regulation of several metabolic pathways, including the inhibition of ER stress and mTOR signaling, which are activated during SARS-CoV-2 infection. Sulfodyne® also decreased SARS-CoV-2 mediated inflammatory responses by inhibiting the delayed induction of IFNB1 and type I IFN-stimulated genes in infected epithelial cell lines and by reducing the activation of human by-stander monocytes recruited after SARS-CoV-2 infection. In K18-hACE2 mice infected with SARS-CoV-2, Sulfodyne® treatment reduced both early lung viral load and disease severity by fine-tuning IFN-beta levels. Altogether, these results provide evidence for multiple mechanisms that underlie the antiviral and anti-inflammatory activities of Sulfodyne® and pinpoint Sulfodyne® as a potent therapeutic agent against pathogenic effects of SARS-CoV-2 infection.

26 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CMCharly Le Maout
Charly Le Maout
LFLucine Fahy
Lucine Fahy
LRLaurent Renou
Laurent Renou
CDCaroline Devanand
Caroline Devanand
CDCharlotte Duwat
Charlotte Duwat
VPVanessa Petit
Vanessa Petit
Background T-cell acute lymphoblastic leukemia (T-ALL) is a malignant hematological disorder characterized by an increased proliferation of immature T lymphocytes precursors. T-ALL treatment includes chemotherapy with strong side effects, and patients that undergo relapse display poor prognosis. Although cell-intrinsic oncogenic pathways are well-studied, the tumor microenvironment, like inflammatory cellular and molecular components is less explored in T-ALL. We sought to determine the composition of the inflammatory microenvironment induced by T-ALL, and its role in T-ALL progression. Methods Two mouse T-ALL cell models were injected into immunocompetent mice. We used anti-Ly6G, and clodronate liposomes to suppress neutrophils and phagocytes, respectively. 5’- (N-ethylcarboxamido)adenosine (NECA), an agonist of adenosine receptors was used to decrease inflammatory molecules secretion. Findings We show that T-ALLs enhance blood neutrophils and resident monocytes, accompanied with a plasmatic acute secretion of inflammatory molecules. Depleting neutrophils or resident monocytes does not modulate plasmatic inflammatory molecule secretion and mice survival. However, inhibiting the secretion of inflammatory molecules by microenvironment with NECA diminishes T-ALL progression enhancing mouse survival. We uncovered Hepatocyte Growth Factor (HGF), T-ALL-driven and the most decreased molecule with NECA, as a potential therapeutic target in T-ALL. Interpretation Altogether, we identified a signature of inflammatory molecules that can potentially be involved in T-ALL evolution and uncovered HGF as a new potential therapeutic target. Fundings The work was supported by CEA, Inserm, Université Paris-Saclay and Université Paris-Cité, la Recherche contre le Cancer (ARC) and Hope of Princess Manon charity. The LSHL team is labellised by Ligue Nationale Contre le Cancer. Evidence before this study T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and lethal hematologic malignancy accounting for about 15% of pediatric and 25% of adult ALL. T-ALL originates from a block of differentiation and uncontrolled proliferation of immature T cells. Current chemotherapies provide an overall 5 years survival higher than 90% in children and of about 50% in adults. Both pediatric and adult relapses have a very poor outcome with resistance to treatment. Therefore, the identification of molecular targets and the development of new specific therapies are major goals to improve treatment success, and one way to reach this goal is to have a better understanding the dialog between T-ALL cells and their microenvironment. Cellular and molecular actors in the microenvironment have been identified to impact several types of leukemia. Recently, the supportive role of myeloid cells has been described in T-ALL. Moreover, interactions between receptors and ligands such as DL1, IL-18, IL-7, IGF1 and CXCL12 sustain proliferation, survival or initiation of T-ALL. However, the composition and the contribution of the inflammatory microenvironment that may broadly help T-ALL progression still remains poorly explored. Added value of this study The study, utilizing NOTCH1 and TAL1/LMO1-driven mouse T-ALL models, reveals that T-ALL induces an inflammatory microenvironment characterized by increased levels of blood neutrophils, resident monocytes, and plasmatic inflammatory molecules. Targeting molecular microenvironment with the non-selective adenosine receptor agonist NECA drastically decreases T-ALL progression and prolongs mice survival. This study further identifies hepatocyte growth factor (HGF), a known regulator of proliferation and migration of tumor cells, as a putative supportive and targetable factor in T-ALL. Implications of all the available evidence In this study, evidence linking T-ALL and inflammatory microenvironment is provided. These data extend our understanding of the biological function of inflammatory microenvironment in T-ALL progression, and open to the targeting of the inflammatory microenvironment, and more specifically HGF/cMet signaling in T-ALL. Such targeted therapeutic approach could be added to current treatments to improve patient outcome.